An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection

Published 2017 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
Authors
Keywords
CD3 bispecific, MABEL, First-in-human dose, Oncology drug development
Journal
REGULATORY TOXICOLOGY AND PHARMACOLOGY
Volume 90, Issue -, Pages 144-152
Publisher
Elsevier BV
Online
2017-09-05
DOI
10.1016/j.yrtph.2017.09.001

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.